F9 and hemophilia B: While the largest set of in vivo genome editing trials was focused on treatment of cervical cancer, early use of in vivo ZFN gene editors was aimed to treat hemophilia B by replacing disease causing mutations in the F9 gene, which causes a deficiency of blood coagulation factor IX [90,91].